Home / Health / Deafness Defied: Singer's "Life-Changing" Double Implants
Deafness Defied: Singer's "Life-Changing" Double Implants
6 May
Summary
- Janine Roebuck, 72, praised surgery after concealing deafness for 30+ years.
- Nationwide trial investigates double cochlear implants for adults.
- Current NHS guidelines largely restrict deaf adults to one implant.

A groundbreaking trial is underway to assess the efficacy of double cochlear implants for adults, offering new hope for thousands of NHS patients. Janine Roebuck, a 72-year-old opera singer from London, has shared her transformative experience with bilateral implants, which she received after living with concealed deafness for over thirty years.
Roebuck, who performed despite her deteriorating hearing, underwent a single cochlear implant in 2019 as per existing guidelines. She later opted for a second implant privately, describing the bilateral experience as vastly superior in sound clarity and spatial awareness.
The current National Institute for Health and Care Excellence (Nice) guidelines generally restrict deaf adults to unilateral implants, primarily due to cost-effectiveness. This new government-funded study, led by Addenbrooke's Hospital and the University of Cambridge, aims to gather robust evidence on the benefits of double implants.
This extensive trial involves over 250 adults across 14 hospitals, comparing outcomes for those receiving one versus two implants. Researchers are focusing on individuals who have lost their hearing later in life and have not previously received an implant. Early indications suggest bilateral implants provide a more natural, three-dimensional hearing experience, akin to what children routinely receive.
Experts believe that offering adults the same hearing opportunities as children could significantly reduce social isolation, enhance communication, improve mental well-being, and boost overall quality of life. The findings from this trial will eventually be submitted to Nice for review, potentially leading to revised guidelines and wider access to this revolutionary treatment.